stockrowScholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
- EPS
- +14.3%
- Free cash flow
- +8.88%
- Total debt
- +294.3%
Quarter to June 2026, against a year earlier
Follow SRRK
Alert me
Scholar Rock Holding Corporation (SRRK) Total debt
Scholar Rock Holding Corporation's total debt at the end of fiscal 2025 was $99.7M, up 98.8% from $50.1M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $196.2M. Over the past ten years it has ranged from $24.0K (fiscal 2018) to $99.7M (fiscal 2025) — the current reading is the highest in ten years. Scholar Rock Holding Corporation ranks 59th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $99.7M | 98.84% |
| FY2024 | $50.1M | 3.00% |
| FY2023 | $48.7M | (2.13%) |
| FY2022 | $49.7M | 2.73% |
| FY2021 | $48.4M | 96.20% |
| FY2020 | $24.7M | 492.13% |
| FY2019 | $4.2M | 17,266.67% |
| FY2018 | $24.0K | (93.97%) |
| FY2017 | $398.0K | (61.09%) |
| FY2016 | $1.0M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $196.2M | (0.21%) |
| Mar 2026 | $196.6M | 97.19% |
| Dec 2025 | $99.7M | 0.10% |
| Sep 2025 | $99.6M | 100.20% |
| 28 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $2.8B |
| COGT Cogent Biosciences, Inc. compare | $223.5M |
| SRRK Scholar Rock Holding Corporation | $196.2M |
| KOD Kodiak Sciences Inc. compare | $174.5M |
| ERAS Erasca, Inc. compare | $56.8M |
| CGON CG Oncology, Inc. compare | $3.0M |
| IMVT Immunovant, Inc. compare | $614.0K |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| MANE Veradermics Incorporated compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on SRRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement